QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT 期刊论文 Journal of Clinical Oncology, 2016, 卷号: 34 作者:  Peeters M., Kim T.W., Li J., Cascinu S., Ruff P., Suresh A.V., Thomas A., Tjulandin S., Guan X., Hoang T., Hei Y.J., Price T.J. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05 Efficacy of panitumumab vs cetuximab in patients with wildtype KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT 期刊论文 Journal of Clinical Oncology, 2016 作者:  Peeters M., Kim T.W., Li J., Cascinu S., Ruff P., Suresh A.V., Thomas A., Tjulandin S., Guan X., Price T.J. 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05 Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) 期刊论文 Journal of Clinical Oncology, 2016 作者:  Price T.J., Kim T.W., Li J., Cascinu S., Ruff P., Suresh A.V., Thomas A., Tjulandin S., Guan X., Peeters M. 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/13